Elecoglipron

Phase 3

AstraZeneca

Elecoglipron is one of 88 therapeutic programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 2 Diabetes MellitusRecruiting

ObesityRecruiting

Type 2 Diabetes MellitusPhase 3

Recruiting

ObesityPhase 3

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 2

NNC0487-0111

Novo Nordisk

Phase 3

11 3

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

4 4

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 5

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 6

Zenagamtide

Novo Nordisk

Phase 3

3 7

Ribupatide

KKailera

Phase 3

3 8

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 9

Elecoglipron

AstraZeneca

Phase 3

1 10

Avapro

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Study completion

NCT07534592

Q2 2028

Phase 3Recruiting

Obesity

NCT07775404

Phase 3Recruiting

Type 2 Diabetes Mellitus

NCT07662213

Phase 3Recruiting

Type 2 Diabetes Mellitus

NCT07664553

Q3 2028

Phase 3Recruiting

Type 2 Diabetes Mellitus

NCT07662109

Phase 3Recruiting

Type 2 Diabetes Mellitus

NCT07662135

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662213·1,200 enrolled

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662135·900 enrolled

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662109·2,000 enrolled

Show 2 more trials

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662044·800 enrolled

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07664553·600 enrolled

Heart Failure With Preserved Ejection Fraction (HFPEF)1 trial

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07761117·6,950 enrolled

Weight Management1 trial

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07667803·4,500 enrolled

Chronic Kidney Disease1 trial

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07753993·7,000 enrolled

Obesity1 trial

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07775404·351 enrolled

1 more indication

Unspecified1 trial

An Open-label, Fixed-sequence Study to Assess the Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07534592·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Elecoglipron. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Elecoglipron. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AstraZeneca

Elecoglipron

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q3 2028

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

Heart Failure With Preserved Ejection Fraction (HFPEF)1 trial

Weight Management1 trial

Chronic Kidney Disease1 trial

Obesity1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News